Erratum: is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?

_Nature Clinical Practice Rheumatology_ (2007) 3: 378–379 [doi:10.1038/ncprheum0530] Due to an author miscommunication, the statement published in the above article “The authors have

declared they have no competing interests.” is incorrect. DM Black has received honoraria from Merck and Nycomed, and research support from Novartis. He has also acted as a consultant for

Roche. CJ Rosen declared he has no competing interests. Authors * Dennis M Black View author publications You can also search for this author inPubMed Google Scholar * Clifford J Rosen View

author publications You can also search for this author inPubMed Google Scholar ADDITIONAL INFORMATION The online version of the original article can be found at 10.1038/ncprheum0530 RIGHTS

AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Black, D., Rosen, C. Erratum: Is risedronate or alendronate more effective at preventing nonvertebral fractures

in women with osteoporosis?. _Nat Rev Rheumatol_ 3, 420 (2007). https://doi.org/10.1038/ncprheum0563 Download citation * Issue Date: July 2007 * DOI: https://doi.org/10.1038/ncprheum0563

SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to

clipboard Provided by the Springer Nature SharedIt content-sharing initiative